DCA history

Dichloroacetate, or DCA, first entered clinical practice in 1983, when doctors began using it to help children with congenital lactic acidosis, a rare and life-limiting mitochondrial disorder. For many of these children, DCA offered something simple yet profound: the chance to feel better and to live with fewer complications. ^(1), (2)

DCA works by gently stimulating an enzyme system in the mitochondria called the pyruvate dehydrogenase complex. When this pathway begins functioning again, the body can shift back toward normal energy production. As a result, lactate levels fall, metabolic acidosis eases, and children often experience clearer thinking, better strength, and improved day-to-day comfort.

Over the years, clinical trials taught researchers how to use DCA safely and effectively – how to find the right dose, how to monitor treatment, and how to watch for side effects. These long-term studies also confirmed that most children tolerated DCA well, giving families and clinicians confidence as they navigated a difficult condition.

Perhaps most importantly, this early work laid the foundation for everything that came next. The careful observation of children with congenital lactic acidosis helped scientists understand DCA’s broader role in human metabolism, opening the door to research in many other illnesses shaped by disrupted energy pathways.

To this day, DCA remains an important option for children born with mitochondrial disorders – one of the few treatments aimed not at masking symptoms, but at helping the cells work as they were meant to. ⁽³⁾

DCA’s story took an important turn in 1987, when researchers began exploring whether this modest molecule could play a role in recovery after two of the most serious medical emergencies: ischemic stroke and heart attack. While the conditions are different, both share a common problem – tissues suddenly starved of oxygen struggle to produce energy, and harmful by-products, especially lactate,begin to build up.

Scientists noticed that DCA could gently intervene in this process. By helping the mitochondria restore a more efficient form of energy production, DCA reduces the excess lactate that accumulates in injured brain or heart tissue after oxygen has been cut off. This matters because high lactate levels often worsen inflammation and impair healing, increasing the risk of long-term disability.

In studies of heart attack recovery, DCA showed another encouraging effect: it helped the injured heart muscle contract more effectively, improving overall function during a vulnerable period. While it is not a replacement for urgent medical treatment, DCA’s ability to support cellular recovery opened a new line of thinking – perhaps metabolic repair could work alongside traditional therapies to improve outcomes.

These early findings did not lead to widespread clinical use, but they played a quiet, meaningful role in shaping how researchers understood DCA. By studying the heart and brain under extreme stress, scientists learned more about how DCA steadies disrupted metabolism, a lesson that would later guide its exploration in other complex conditions. ^{(1), (2)}

The story of DCA and cancer began in 2007, almost by chance. A research group led by Dr. Evangelos Michelakis was studying DCA as a possible treatment for heart disease when they noticed something unexpected: cancer cells behaved very differently from normal cells in how they used energy. Their mitochondria – the cell’s energy centers – were disrupted in a way that DCA seemed able to correct.

Curious about this observation, the team tested DCA in laboratory models of brain, breast, and lung cancer. The results were striking. Tumor cells began to die, and in some cases the tumors shrank within hours, while healthy cells remained largely unaffected. The mice appeared to handle DCA comfortably, without unexpected or troubling side-effects.

This observation, modest at first glance, became a doorway to understanding cancer through its metabolic vulnerabilities. It suggested that cancer might be influenced not only by genetics but also by faulty cellular metabolism, and that restoring this balance could weaken tumors from within. When the initial results were published, they generated international interest and sparked a wave of new studies, both in the laboratory and in early human trials. ^{(DCA Cancer Research)}

Progress, however, was slowed by a practical reality: DCA is inexpensive and not patentable, offering little financial incentive for large pharmaceutical companies to invest in further trials. Even so, dedicated researchers continued to build evidence through smaller studies and clinical experience. ^{(1) (2)}

Today, DCA is used in various integrative clinics around the world – sometimes on its own, sometimes alongside conventional or alternative therapies – as part of a growing effort to bring metabolic treatments into modern oncology. ^{(DCA Clinics)}

Pulmonary Arterial Hypertension (PAH) is a condition where the blood vessels in the lungs become stiff and narrow, making it harder for blood to flow and get oxygen. This results in a variety of symptoms, including shortness of breath, fatigue, and even heart failure in severe cases. It’s a progressive disease, meaning it gets worse over time.

In 2017, one of the first clinical studies exploring the use of Sodium Dichloroacetate (DCA) for PAH was completed. Researchers in Canada discovered that in PAH, the muscle cells in the pulmonary arteries start behaving like tumor cells. These changes were believed to be driven by alterations in cellular metabolism, which could potentially be corrected. ⁽¹⁾

The team decided to test this theory with DCA, a compound already used in certain metabolic disorders. The results were encouraging. In a clinical trial involving 20 participants, those with PAH who took DCA showed a noticeable improvement in their lung function within just 1-3 months. The patients reported reduced symptoms, like shortness of breath, and a significant boost in physical recovery. ⁽²⁾

Interestingly, DCA was most effective when combined with other PAH treatments, such as Sildenafil, suggesting that it could become part of a broader treatment strategy.

This study offers a glimmer of hope for those living with PAH, showing that a small molecule might play a role in improving quality of life and symptom management in this challenging disease.

In 2018, a pilot trial conducted in Belgium found that DCA could offer significant relief to people suffering from Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS). Over half of the participants reported a 60% improvement in their fatigue levels, a remarkable change for individuals enduring such debilitating exhaustion. Following the trial, many people in the ME/CFS online community who adopted a similar DCA protocol also reported comparable improvements in their symptoms. ⁽¹⁾

ME/CFS is often thought to be linked to dysfunction in the mitochondria, the tiny powerhouses within our cells responsible for generating energy. When these mitochondria become impaired, it leads to the kind of extreme fatigue that defines the condition. DCA steps in here by helping restore mitochondrial function, which may explain why some patients experience increased energy levels and overall improvements in their well-being after using it.

The original DCA protocol for ME/CFS also incorporates specific supplements designed to support mitochondrial health, further boosting the benefits of DCA. While DCA alone isn’t a cure-all, it plays a critical role in helping those with ME/CFS regain some of the energy they’ve lost, potentially improving their quality of life. For many, this represents a glimmer of hope in managing a condition that has long had few treatment options.

Endometriosis affects 1 in 10 women, bringing chronic pain, heavy periods, and fertility struggles. For many, it feels like an invisible burden – one that impacts every part of life. For years, women have battled this condition, often facing misdiagnoses and countless hospital visits, only to find relief through an unlikely source: DCA (Sodium dichloroacetate). Originally used to treat congenital lactic acidosis in children, this compound has now shown promise in easing the painful symptoms of endometriosis. ^(1), (2)

In 2019, researchers at the University of Edinburgh discovered that DCA could help manage endometriosis symptoms. ⁽³⁾

Endometriosis occurs when tissue similar to the uterine lining grows outside the womb, causing internal bleeding, inflammation, and scarring. This tissue processes energy differently from healthy cells, producing higher levels of lactate. DCA has shown promise in reducing lactate levels, easing the stress on these cells, and shrinking the painful lesions.

In clinical trials, women taking DCA reported a significant reduction in pain and a decreased need for pain medication. Some of them even conceived after a long period of infertility, something they had struggled with for years. 

This discovery is more than just a potential treatment – it’s a beacon of hope. For those living with endometriosis, the possibility of a non-hormonal, non-surgical treatment could change everything. With further trials underway, DCA could soon offer a game-changing alternative to current treatments. ⁽⁴⁾